- Home
- AMSF vs AQST Comparison
AMSF vs AQST Comparison
Compare AMSF & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMSF | AQST |
|---|---|---|
| Founded | 1985 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.3M | 529.4M |
| IPO Year | 1996 | 2007 |
Fundamental Metrics
Financial Performance| Metric | AMSF | AQST |
|---|---|---|
| Price | $30.48 | $3.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $46.33 | $9.00 |
| AVG Volume (30 Days) | 224.1K | ★ 2.2M |
| Earning Date | 04-22-2026 | 05-01-2026 |
| Dividend Yield | ★ 8.61% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $317,252,000.00 | $67,430,000.00 |
| Revenue This Year | $8.45 | $10.08 |
| Revenue Next Year | $6.03 | $49.60 |
| P/E Ratio | $70.33 | ★ N/A |
| Revenue Growth | ★ 2.66 | 0.77 |
| 52 Week Low | $29.42 | $2.94 |
| 52 Week High | $47.86 | $7.55 |
Technical Indicators
Market Signals| Indicator | AMSF | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 36.40 | 34.00 |
| Support Level | $29.63 | $3.16 |
| Resistance Level | $32.11 | $4.38 |
| Average True Range (ATR) | 1.03 | 0.18 |
| MACD | -0.56 | -0.05 |
| Stochastic Oscillator | 8.88 | 10.81 |
Price Performance
Historical ComparisonAbout AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums. The Company operates as a single reportable segment, Insurance Operations.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.